Phase 2 Stomach Cancer Trial, Recruiting NCT07151040 Sponsor: One-carbon Therapeutics AB Condition: Stomach Cancer
Back to Stomach Cancer

Phase 2 Stomach Cancer Trial, Recruiting

NCT07151040
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have given written consent to participate in the study
  • People who have been diagnosed with advanced cancer confirmed by laboratory tissue testing — specifically colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer, or gastric cancer (including cancer at the junction of the stomach and oesophagus)
  • People who have already received at least one round of chemotherapy or similar drug treatment for cancer that has spread or cannot be surgically removed
  • People who are 18 years of age or older
  • People who are willing to follow the study procedures throughout the trial

Who may not be able to join:

  • People who have a history of, or currently have, any significant health conditions that the trial doctor considers medically important (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +46708555182

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
One-carbon Therapeutics AB
Registry
ClinicalTrials.gov
Start date
22 August 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇫🇷 France 🇪🇸 Spain 🇬🇧 United Kingdom

Primary endpoints

Frequency of treatment-emergent adverse events (TEAEs); Incidence of severe treatment-emergent adverse events (TEAEs) per Common Terminology for Adverse Events (CTCAE) V5.0 grading; Incidence of treatment-emergent adverse events (TEAEs) related to treatment, as assessed by the Investigator; Frequency of serious adverse events (SAEs); Incidence of serious adverse events (SAEs) per the seriousness criteria defined in the protocol.; Incidence of serious adverse events (SAEs) related to treatment, as assessed by the Investigator; Incidence of out of range clinical laboratory tests (as defined by t...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov